Promising combo for tough hodgkin lymphoma cases

NCT ID NCT03016871

Ongoing Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new treatment plan for people with Hodgkin lymphoma that returned or didn't respond to initial therapy. The approach combines an immunotherapy drug (nivolumab) with standard chemotherapy (ICE) to shrink the cancer before a stem cell transplant. The goal was to see how well this combination works and what side effects it causes. The study included 78 adults who had already tried at least one treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT HODGKIN LYMPHOMA REFRACTORY HODGKIN LYMPHOMA

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States
Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109, United States
M D Anderson Cancer Center

Houston, Texas, 77030, United States
Yale University

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.